Reviewer's report

Title: Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts

Version: 1 Date: 30 August 2010

Reviewer: Esther A Guzman

Reviewer's report:

This is a well-written, sound report that could have impact on the field. The question posed by the authors is well defined, and the methods used are appropriate and well described.

Discretionary revisions

1. A brief description as to why the oral dosage in addition to the intraperitoneal injection was necessary for this compound would be useful for those of us not familiar with this agent.

2. While the cell cycle figure has all the pertinent data to support the authors’ conclusions, the way it is presented made it a bit difficult to follow the conclusions. Perhaps clearly labeling the G1, S, G2/M percentages may make it easier to appreciate the changes the authors saw.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests